Diabetes Prevention Program referral

The Diabetes Prevention Program in Pain and Primary Care

The Diabetes Prevention Program is a coached lifestyle intervention targeting 7 percent weight loss and 150 minutes of weekly activity. A referral from a pain or primary care practice should carry a documented baseline (A1c, fasting glucose, fasting insulin, kidney function and body composition) and an early recheck, because participants who see a result stay.

Lifestyle intervention cut diabetes incidence by more than half in the trial that defined it. At national scale it reaches a sliver of eligible adults and delivers least to those at highest risk.

The Diabetes Prevention Program is the strongest randomized evidence in American medicine that a coached lifestyle intervention changes metabolic outcomes, and it is also the clearest demonstration that proof is not delivery. For primary care, pain, endocrine and geriatric practices the practical question is not whether to refer. It is what should travel with the referral, and what measurement keeps the effect from leaking away between enrollment and week 52. The chapter video, Empowered Individuals Change Their Communities, presents the final chapter of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD; source-level grading is in the book companion for chapter 22.

How well does the Diabetes Prevention Program work?

The original trial randomized 3,234 adults with impaired glucose tolerance to placebo, metformin or a lifestyle program targeting 7 percent weight loss and 150 minutes of weekly activity. Over an average of 2.8 years, lifestyle reduced diabetes incidence by 58 percent and metformin by 31 percent, with 6.9 people needing the lifestyle program over three years to prevent one case. At 15 years the lifestyle hazard ratio was still 0.73, though cumulative incidence had reached 55 percent against 62 percent on placebo, and at 21 years the cumulative reduction stood at 24 percent.

The ceiling came from established diabetes. Look AHEAD randomized 5,145 adults with type 2 diabetes to intensive lifestyle intervention; weight fell 8.6 percent at one year, and the cardiovascular composite did not differ, a hazard ratio of 0.95. What it did deliver was remission in 11.5 percent at one year against 2.0 percent with education.

Where national scale loses the effect

Scaled nationally, the program enrolled 455,954 people in eight years, set against an at-risk adult population of more than 88 million. Among the first 14,747 participants, median attendance was 14 sessions, 35.5 percent reached the 5 percent weight-loss goal, and each additional session was worth 0.3 percent of body weight. In-person delivery produced 4.4 percent average weight loss against 2.6 percent online, and participants who stayed for 22 sessions exceeded the 5 percent goal in every format.

The losses concentrate where risk is highest. In-person weight loss ran 5.1 percent in non-Hispanic White participants against 3.3 percent in non-Hispanic Black and American Indian or Alaska Native participants, and 3.3 percent at ages 18 to 34 against 5.1 percent at 65 and older. Early success predicted staying: 41.0 percent of those who had lost nothing were retained, against 73.9 percent of those who had lost at least half a percent. Medicare has covered the program since 2018; in six years 9,015 beneficiaries participated, against roughly 5.2 million eligible, with about 1.5 delivery sites per 100,000 beneficiaries.

What should a Diabetes Prevention Program referral include?

The retention data argue for a documented baseline and an early recheck, because participants who see a result stay. That baseline should include more than glucose.

• A1c and fasting glucose, with remission and progression defined in advance.
• Fasting insulin or a HOMA-IR estimate, because insulin resistance can move substantially while glucose moves little; one company-funded remote-care cohort reported a 55 percent fall in HOMA-IR at one year.
• Kidney function. In 1,779 Diabetes Prevention Program participants reassessed about 21 years after randomization, painful neuropathic symptoms tracked weight and lower eGFR and were not associated with glycemia.
• Body composition, particularly when BMI is under 27. In 20 people with type 2 diabetes at that BMI, a 6.5 percent weight loss produced remission in 70 percent, and roughly one in six patients is diagnosed at that weight.
• A weight target expressed as a percentage, with the musculoskeletal threshold noted for pain patients: knee osteoarthritis relief was anticipated at about 7 percent loss.

For pain practices the musculoskeletal evidence is real and modest. Weight-loss interventions improved osteoarthritis pain by a standardized 0.54 against minimal care but were not better than exercise alone in knee osteoarthritis; pair the referral with dosed movement. Effects on pain beyond the joints are inferred from mechanism.

Who should be referred to a Diabetes Prevention Program?

• Adults with prediabetic glycemia, including those previously told their A1c was nothing to worry about.
• Chronic pain patients with a metabolic phenotype: elevated glucose or A1c, a high triglyceride-to-HDL ratio, central adiposity.
• Patients with type 2 diabetes and a normal BMI, in whom body composition changes the conversation.
• Patients with painful neuropathic symptoms, where weight and kidney function deserve measurement alongside glycemia.
• Household members of enrolled patients, since untreated spouses in lifestyle trials lost weight alongside the enrolled partner.

Practice criteria are summarized under selection criteria.

Measurement as the retention tool

Education has a dose and a half-life. Diabetes self-management education lowered A1c by 0.57 on average with ten or more contact hours as the threshold, and pooled trajectories after face-to-face education showed an early reduction of about 1.3 percent drifting back toward baseline by 52 weeks, independent of program intensity. Feedback holds part of the gain: continuous glucose monitoring added 0.29 over fingersticks, and among 9,768 smart-scale users a gap of 30 days without weighing was associated with 1.37 kilograms of gain in those with obesity.

Measura [Cardiometabolic and Autonomic Health Analysis] supplies the office-based side of that feedback loop. It is a testing service that reports to the ordering physician and does not treat or diagnose disease on its own. Laboratory panels provide the glycemic, lipid and renal markers, and bioimpedance body composition separates fat and lean mass so that a participant losing muscle is not recorded as a success. Repeat measurement at defined intervals turns a referral into a tracked episode rather than a handoff; the case for standing orders applies directly.

The consultation is part of the dose

How the referral is delivered changes what it does. In a 1987 trial of 200 general practice patients without a definite diagnosis, 64 percent were better at two weeks after a positive consultation against 39 percent after a negative one, while treatment itself made little difference. In 406 patients with newly chronic back pain, each point of perceived risk that the pain would persist slowed recovery at a hazard ratio of 0.91. Among 720 medical inpatients, hopelessness about one’s condition carried an adjusted odds ratio of 5.69 for a positive suicide screen, against 2.29 for chronic pain. Only 15.7 percent of primary care visits included counseling on diet, activity or stress.

Standing orders and documentation

A reproducible workflow is a standing order that attaches A1c, fasting glucose and insulin, a lipid panel, kidney function and body composition to every prevention-program referral, with a scheduled repeat early, when retention is decided, and again before the first year ends, when education effects fade. At an annual wellness visit, the same data support the cardiometabolic documentation tracked under HEDIS and value-based care, as quality documentation rather than an indication in itself. Filing results as structured fields through getting results into the record keeps the trend visible to every clinician in the chain. The mood and metabolic screening that precedes many of these referrals is in depression and insulin resistance screening; patients can read the patient version.

Frequently asked questions

What is a diabetes prevention program?

A coached lifestyle program that targets 7 percent weight loss and 150 minutes of activity a week. In the original trial of 3,234 adults with impaired glucose tolerance, it cut new cases of diabetes by 58 percent over about 2.8 years. The national version has enrolled 455,954 people, and Medicare has covered it since 2018. A referral holds best with a documented baseline and an early recheck.

What did the Diabetes Prevention Program trial show?

In 3,234 adults with impaired glucose tolerance, an intensive lifestyle program cut diabetes incidence by 58 percent and metformin by 31 percent over about 2.8 years, with 6.9 people treated with lifestyle over three years to prevent one case. The benefit narrowed but persisted at 15 and 21 years. The wider basis for measurement is summarized in the clinical rationale.

Why does national enrollment deliver less than the trial?

Reach and retention. The national program enrolled 455,954 people against more than 88 million at risk, average weight loss fell short of 5 percent in every delivery mode, and younger, Black and American Indian participants lost less and left earlier. Participants who stayed 22 sessions exceeded the goal. Outcome implications are discussed in what changes for the patient.

Which baseline measurements should accompany a referral?

A1c and fasting glucose, fasting insulin, a lipid panel, kidney function and body composition, plus a weight target written as a percentage. Kidney function earns its place because painful neuropathic symptoms tracked weight and eGFR rather than glycemia over 21 years of follow-up, and body composition matters in patients with a BMI under 27. Panel options are under laboratory panels.

Is weight loss relevant to chronic pain outcomes?

In osteoarthritis, yes, at a modest size: a standardized 0.54 improvement in pain against minimal care, no better than exercise alone in the knee, and relief anticipated at about 7 percent weight loss. For spinal pain the evidence was limited and inconclusive, so broader pain effects should be documented as inferred from mechanism. Use by specialty is covered under specialty applications.

How often should metabolic measures be repeated after referral?

The retention and education data point to two moments that matter: early in the program, because participants who show initial loss are far more likely to stay, and before the one-year mark, because education effects on A1c attenuate toward baseline by 52 weeks. The exact interval is a clinical decision. Between-visit approaches are in chronic care and between-visit monitoring.

References

• Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., Nathan, D. M., & Diabetes Prevention Program Research Group (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine, 346(6), 393–403. https://doi.org/10.1056/NEJMoa012512
• Diabetes Prevention Program Research Group (2015). Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. The Lancet Diabetes & Endocrinology, 3(11), 866–75. https://doi.org/10.1016/S2213-8587(15)00291-0
• Crandall, J. P., Dabelea, D., Knowler, W. C., Nathan, D. M., Temprosa, M., & Diabetes Prevention Program Research Group (2025). The Diabetes Prevention Program and Its Outcomes Study: NIDDK’s Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact. Diabetes Care, 48(7), 1101–1111. https://doi.org/10.2337/dc25-0014
• Cannon, M. J., Ng, B. P., Lloyd, K., Reynolds, J., & Ely, E. K. (2022). Delivering the National Diabetes Prevention Program: Assessment of Enrollment in In-Person and Virtual Organizations. J Diabetes Res, 2022, 2942918. https://doi.org/10.1155/2022/2942918
• Ely, E. K., Gruss, S. M., Luman, E. T., Gregg, E. W., Ali, M. K., Nhim, K., Rolka, D. B., & Albright, A. L. (2017). A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC’s National Diabetes Prevention Program. Diabetes Care, 40(10), 1331–1341. https://doi.org/10.2337/dc16-2099
• Ng, B. P., Ely, E., Papali’i, M., & Cannon, M. J. (2024). Delivering the National Diabetes Prevention Program: Assessment of Retention, Physical Activity, and Weight Loss Outcomes by Participant Characteristics and Delivery Modes. J Diabetes Res, 2024, 8461704. https://doi.org/10.1155/2024/8461704
• Look AHEAD Research Group, Wing, R. R., Bolin, P., Brancati, F. L., Bray, G. A., Clark, J. M., Coday, M., Crow, R. S., Curtis, J. M., Egan, C. M., Espeland, M. A., Evans, M., Foreyt, J. P., Ghazarian, S., Gregg, E. W., Harrison, B., Hazuda, H. P., Hill, J. O., Horton, E. S., … Yanovski, S. Z. (2013). Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med, 369(2), 145–54. https://doi.org/10.1056/NEJMoa1212914
• Herman, W. H., Ciarleglio, A., Callaghan, B. C., Edelstein, S. L., Goldberg, R., White, N. H., & Albers, J. W. (2025). Nonglycemic and Glycemic Risk Factors for Painful Neuropathic Symptoms and for Distal Symmetrical Polyneuropathy (DSPN) in the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetes Care, 48(10), 1676–1684. https://doi.org/10.2337/dc25-0596
• Taylor, R., Barnes, A. C., Hollingsworth, K. G., Irvine, K. M., Solovyova, A. S., Clark, L., Kelly, T., Martin-Ruiz, C., Romeres, D., Koulman, A., Meek, C. M., Jenkins, B., Cobelli, C., & Holman, R. R. (2023). Aetiology of Type 2 diabetes in people with a ‘normal’ body mass index: testing the personal fat threshold hypothesis. Clinical Science, 137(16), 1333–1346. https://doi.org/10.1042/CS20230586
• Dughmosh, R., Hamdan, A., Moghassabi, W., Al-Kahlout, L., Syed, A., Alwisi, N., Al-Sharif, N., Othman, M., & Doi, S. A. R. (2026). Glycemic trajectory after face-to-face diabetes self-management education: a dose-response meta-analysis. Diabetes Research and Clinical Practice, 238, 113375. https://doi.org/10.1016/j.diabres.2026.113375

Related reading

• Depression and Insulin Resistance: Screening the Pain Patient
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.